Salesforce Stock's Sell-Off Keeps Getting Worse. Is It Finally Time to Buy the Stock?

Salesforce reported fiscal Q1 2027 revenue up 13% year over year to $11.1 billion, with AI and data ARR rising to $3.4 billion, up about 200%, and Agentforce crossing $1 billion in ARR after more than tripling. Non-GAAP operating margin hit a record 34.8% and free cash flow was $6.6 billion, while the company returned $27.5 billion to shareholders, including a $25 billion accelerated buyback that cut share count about 10%. Despite these fundamentals, the stock is down about 40% in 2026 and now trades near 12x forward earnings amid investor concern that AI could pressure software seat-based pricing.

Analysis

The market is treating Salesforce as a proxy short on AI disruption, but the quarter argues the opposite: automation is currently monetizing inside the incumbent stack rather than disintermediating it. The key second-order signal is seat expansion alongside AI adoption, which means customers are layering AI on top of core workflows instead of substituting away from them; that matters because it delays the “fewer seats” bear case by at least several quarters, possibly longer.

The more interesting winner set may sit adjacent to CRM rather than against it. If Salesforce can successfully shift from per-seat to usage-based and outcome-based pricing, the real beneficiary is the category that can attach AI to existing enterprise data and workflow surfaces—vendors with distribution, installed bases, and strong switching costs. Conversely, pure-play point solutions and standalone AI copilots are more exposed to compression because the incumbent is now bundling the same functionality into the control plane customers already pay for.

The stock, however, may remain trapped between improving fundamentals and a valuation regime that has structurally de-rated software duration. At roughly low-teens earnings, downside is increasingly about sentiment and guidance cadence, not business collapse. The critical catalyst window is the next 1-2 quarters: if organic growth re-accelerates without margin giveback, the market can stop pricing CRM as a secular ex-growth name; if not, the buyback can cushion the stock but won’t fully re-rate it.

The contrarian view is that the consensus is overestimating how fast AI converts into net seat destruction in large enterprises. Implementation friction, governance, and workflow inertia tend to slow substitution, while buyers initially pay for both humans and agents. That creates a multi-quarter period where AI increases vendor monetization before it becomes a margin threat, which is exactly the kind of gap that creates mispriced value in large-cap software.

Key Decisions for Investors

• Buy a starter long in CRM over the next 1-2 weeks on weakness, sized small: thesis is sentiment washout has outrun fundamental deterioration; target a 15-20% rebound if organic growth stabilization is confirmed, with 10-12% downside if AI fear reaccelerates.
• Add CRM only on evidence of back-half reacceleration in the next earnings cycle; use a two-step entry rather than full size now to avoid paying for the valuation reset before the catalyst is visible.
• Pair trade: long CRM / short a basket of over-extended AI-native application names that lack installed-base monetization, on the view that incumbent bundling will pressure standalone AI pricing over the next 6-12 months.
• Consider CRM call spreads for a 3-6 month horizon if implied vol remains elevated; the asymmetric setup is modest downside from buybacks versus meaningful upside if the market stops discounting seat erosion.
• Avoid chasing INFA despite strategic adjacency; treat it as a more execution-sensitive way to express the enterprise data/AI theme until integration and cross-sell evidence shows up.